An Alternative Approach for the Assessment of Bioequivalence Between Two Formulations of a Drug
โ Scribed by Dr. Shein-Chung Chow; Dr. Jun Shao
- Publisher
- John Wiley and Sons
- Year
- 2007
- Tongue
- English
- Weight
- 332 KB
- Volume
- 32
- Category
- Article
- ISSN
- 0323-3847
No coin nor oath required. For personal study only.
โฆ Synopsis
Swut rmzry
The problem of the assessment of biocquivalencc bet\sreii Q test forniiilation (T) and a reference formnlation (R) of n drug using a two-way crossover experiment is considered. To claim bioequivalence between two formulations, i t is required by the United States Food and Drug -4dministration (FDA) to dcnionstrate that the true ratio of means p ~/ p ~ of pharinarokinetic parameters of concern falls within some reasonable limits (cs., (80 0/0, 120 %)) with certain assurance. -4 rommonly used approach is to construct a n approximate 90 0,; confidence interval for p ~/ p ~ and, compare it with (80 O,b, 120 0 ; ) . I n this paper, an exact approach according to the FD-I's criteria, is proposed. The proposed procedure is derived by constriirting an exact confidence region (an clli)se) for ( p ~, p ~) and coniparing i t vith t h e region bouiidcd by / 1 ~= 0 . 8 p ~ and /iT=i.2/IR. Iheqitivalence is ronclrided if the ellipse IS within t lie critical region.
๐ SIMILAR VOLUMES
The two-period cross-over design with two sequences of drug administration is a standard experimental design when bioequivalence of one test formulation is to be assessed in comparison with a reference formulation. Previously, an approach based on Fieller's confidence interval has been presented for
## Binding of autoantibodies to the acetylcholine receptor (AChR) plays a major role in the autoimmune disease Myasthenia gravis (MG). In this paper, we propose a structure model of a putative immunocomplex that gives rise to the reduction of functional AChR molecules during the course of MG. The mo